Trial Profile

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ponatinib (Primary) ; Aspirin
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms ResToP

Most Recent Events

27 Dec 2023 Planned End Date changed from 2 Dec 2024 to 1 Dec 2025.
27 Dec 2023 Planned primary completion date changed from 2 Dec 2024 to 1 Dec 2025.
15 Jun 2023 Interim results of PONAZERO (NCT04043676) & RESTOP (NCT04160546) assessing use of ponatinib 15mg daily for 12 months, presented at the 28th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com